國藥股份(600511.SH):證監會對副總經理唐磊因涉嫌內幕交易相關股票予以立案
格隆匯1月9日丨國藥股份(600511.SH)公佈,收到公司副總經理唐磊先生通知,其於近日收到中國證券監督管理委員會出具的《立案吿知書》,根據《中華人民共和國證券法》《中華人民共和國行政處罰法》等法律法規,中國證監會決定對唐磊先生因涉嫌內幕交易相關股票予以立案。
本次立案調查事項系針對唐磊先生個人交易其他公司股票的調查,不涉及本公司股票交易。調查期間,唐磊先生將積極配合相關調查工作。目前本公司各項生產經營活動均正常有序開展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.